Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOMEDE everolimus continuation study in DIPG and diffuse midline glioma
NL-OMON49636Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) (4 arms), sponsored by Gustave Roussy. Primary endpoint: Overall survival. Started Feb 2019; status: completed.
02
Drugs
everolimus
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NL-OMON49636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49636.